Biomarker-Driven Lung Cancer

>

Latest News

Selection of First-Line NSCLC Therapy Influenced by Delayed Testing
Selection of First-Line NSCLC Therapy Influenced by Delayed Testing

March 8th 2024

During a Targeted Oncology™ Case-Based Roundtable™ event, Misako Nagasaka, MD, PhD, asked participants how they would approach therapy for a patient with metastatic non–small cell lung cancer when biomarker testing is not yet completed. This is the second of 2 articles based on this event.

Comprehensive Molecular Testing Needed for Frontline NSCLC Treatment
Comprehensive Molecular Testing Needed for Frontline NSCLC Treatment

February 19th 2024

FDA Grants Avutometinib/Sotorasib FTD in KRAS-Mutated NSCLC
FDA Grants Avutometinib/Sotorasib FTD in KRAS-Mutated NSCLC

January 19th 2024

Evaluating the TKI Inhibitors in Fusion-Driven NSCLC
Evaluating the TKI Inhibitors in Fusion-Driven NSCLC

January 5th 2024

Video Series
Video Interviews

More News